Please login to the form below

Orencia

This page shows the latest Orencia news and features for those working in and with pharma, biotech and healthcare.

Opdivo drives growth at BMS, but US sales slow down

Overall, BMS reported fourth-quarter revenues up 22% to $5.2bn, with a solid showing from novel oral anticoagulant Eliquis (apixaban), which leaped 57% to $346m and rheumatoid arthritis therapy Orencia

Latest news

Opdivo drives gain in BMS sales, but business revamp coming

Away from cancer, rheumatoid arthritis treatment Orencia (abatacept) continued its buoyant run with an 18% increase to $572m, while novel oral anticoagulant Eliquis (apixaban) brought in $884m, a rise of 90%.
Shire gives up on Momenta-partnered Humira biosimilar

It also has a biosimilar collaboration with generics giant Mylan covering six biologics, headed by M834, a biosimilar version of Bristol-Myers Squibb's rheumatoid arthritis drug Orencia (abatacept).
Mylan buys into six biosimilars, including Orencia candidate

The agreement gives Mylan the rights to six biosimilars in Momenta's pipeline, including a version of Bristol-Myers Squibb's rheumatoid arthritis therapy Orencia (abatacept) which brought in sales of
NICE backs four treatments for juvenile idiopathic arthritis

Includes BMS' Orencia and AbbVie's Humira. NICE has recommended four drugs in draft guidance for the treatment of juvenile idiopathic arthritis (JIA). ... The institute backed Bristol-Myers Squibb's Orencia (abatacept), AbbVie's Humira (adalimumab),
NICE backs biosimilars in rheumatoid arthritis guidance

Orencia (abatacept) and MSD/J&J's Remicade (infliximab).

More from news
Approximately 8 fully matching, plus 27 partially matching documents found.

Latest Intelligence

Deal Watch January 2016

255. Mylan/ Momenta. Co-development, co-commercialisation . Exclusive global collaboration with Momenta for 6 biosimilars including a biosimilar version of Orencia (abatacept) . 245. Athersys/ Healios. Licence. Development and commercialisation
Biosimilars - the same, but different?

Orencia and Actemra for rheumatoid arthritis.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

BMS’ Brian Daniels to retire

Dr Daniels has been with BMS since 2000 as VP of the immunology, pulmonary, and dermatology therapeutic area where he worked on such compounds as rheumatoid arthritis drug Orencia (abatacept).

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

Brand leaders in RA will lose market share, predict rheumatologists

leaders Enbrel (etanercept) and Humira (adalimumab) will continue to lose market share to newer biologics such as RoActemra (tocilizumab), Orencia (abatacept) and Simponi (golimumab) and may experience strong competition from biosimilar

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Editorial Assistant Medical Education Agency: £25, 000 - £26, 000

Home-based Senior Project Manager – Independent Med Ed: Salary TBC

Client Services Director – Medical Education Agency – North West...: Salary TBC

PRINCIPAL MEDICAL WRITER > ETL - LONDON / NEW YORK/ HOME - ME...: Salary TBC

Technical Manager – Developer and Commercial Excellence, Healthc...: Excellent package

Medical Writer: Salary TBC

Account Director – Healthcare Marketing – Berks: Salary TBC

Engagement Expert, Healthcare Brand Communications, London: Excellent package

Senior Account Manager, Rare Diseases – Medical Communications, ...: Excellent package

Account Director, Healthcare Marketing Agency: Salary TBC

Senior Medical Writer: Salary TBC

Account Manager / Senior Account Manager: 35, 000-40, 000

Account Manager / Account Director: Competative

Global Business Development Director – Health Education: excellent commission

Engagement Specialist, Healthcare Brand Communications, London, ...: circa £50K

Associate Director: £75, 000-90, 000

Account Director, Medical Education: Salary TBC

Senior Account Director development role to Business Director, H...: Excellent package

Account Director – Health Policy – Global Agency: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

infill healthcare communication

infill is a dynamic and innovative, international healthcare agency with >25 years' experience in delivering healthcare communication, medical education and...

Latest intelligence

Unlocking the potential of science and technology in the UK: Greater collaboration is vital in post-Brexit UK, says Alderley Park leader...
NHS regional footprints: What to expect from 2019...
Not another weight-loss ad: Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...